CN113906028A - 稠合杂环衍生物 - Google Patents
稠合杂环衍生物 Download PDFInfo
- Publication number
- CN113906028A CN113906028A CN202080039617.8A CN202080039617A CN113906028A CN 113906028 A CN113906028 A CN 113906028A CN 202080039617 A CN202080039617 A CN 202080039617A CN 113906028 A CN113906028 A CN 113906028A
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- alkyl
- formula
- hbv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853533P | 2019-05-28 | 2019-05-28 | |
| EP19176933.0 | 2019-05-28 | ||
| US62/853533 | 2019-05-28 | ||
| EP19176933 | 2019-05-28 | ||
| CNPCT/CN2020/085720 | 2020-04-20 | ||
| CN2020085720 | 2020-04-20 | ||
| PCT/US2020/034643 WO2020243135A1 (en) | 2019-05-28 | 2020-05-27 | Fused heterocyclic derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113906028A true CN113906028A (zh) | 2022-01-07 |
Family
ID=71741889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080039617.8A Pending CN113906028A (zh) | 2019-05-28 | 2020-05-27 | 稠合杂环衍生物 |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3976617B1 (https=) |
| JP (1) | JP2022535734A (https=) |
| KR (1) | KR20220012913A (https=) |
| CN (1) | CN113906028A (https=) |
| AU (1) | AU2020285718A1 (https=) |
| BR (1) | BR112021022889A8 (https=) |
| CA (1) | CA3138168A1 (https=) |
| CL (1) | CL2021003155A1 (https=) |
| CO (1) | CO2021016433A2 (https=) |
| CR (1) | CR20210666A (https=) |
| DO (1) | DOP2021000230A (https=) |
| IL (1) | IL288322A (https=) |
| JO (1) | JOP20210313A1 (https=) |
| MA (1) | MA56043A (https=) |
| MX (1) | MX2021014575A (https=) |
| PE (1) | PE20220767A1 (https=) |
| PH (1) | PH12021552974A1 (https=) |
| SG (1) | SG11202113167QA (https=) |
| WO (1) | WO2020243135A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024114709A1 (en) * | 2022-12-01 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | A crystal form of a fused heterocycle derivative compound |
| WO2024140851A1 (zh) * | 2022-12-28 | 2024-07-04 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116744927A (zh) * | 2020-12-02 | 2023-09-12 | 杨森科学爱尔兰无限公司 | 稠合杂环衍生物及其在治疗hbv感染中的用途 |
| WO2022116999A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives and their use in the treatment of hbv infection |
| WO2022116998A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives as hbv inhibitors |
| WO2022253255A1 (en) * | 2021-06-02 | 2022-12-08 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives |
| CN117715909A (zh) | 2021-06-02 | 2024-03-15 | 杨森科学爱尔兰无限公司 | 稠合杂环衍生物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107531691A (zh) * | 2014-12-30 | 2018-01-02 | 诺维拉治疗公司 | 治疗乙型肝炎感染的衍生物和方法 |
| WO2018005881A1 (en) * | 2016-06-29 | 2018-01-04 | Novira Therapeutics, Inc. | Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections |
| US20180186789A1 (en) * | 2014-09-08 | 2018-07-05 | Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh | Pyrazolopyridine derivatives and their use in therapy |
| CN109641896A (zh) * | 2016-06-29 | 2019-04-16 | 诺维拉治疗公司 | 二氮杂酮衍生物及其在治疗乙型肝炎感染中的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202111236UA (en) * | 2019-04-30 | 2021-11-29 | Aicuris Gmbh & Co Kg | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
-
2020
- 2020-05-27 WO PCT/US2020/034643 patent/WO2020243135A1/en not_active Ceased
- 2020-05-27 KR KR1020217042210A patent/KR20220012913A/ko not_active Withdrawn
- 2020-05-27 AU AU2020285718A patent/AU2020285718A1/en not_active Abandoned
- 2020-05-27 MA MA056043A patent/MA56043A/fr unknown
- 2020-05-27 CR CR20210666A patent/CR20210666A/es unknown
- 2020-05-27 PH PH1/2021/552974A patent/PH12021552974A1/en unknown
- 2020-05-27 BR BR112021022889A patent/BR112021022889A8/pt unknown
- 2020-05-27 SG SG11202113167QA patent/SG11202113167QA/en unknown
- 2020-05-27 EP EP20744199.9A patent/EP3976617B1/en active Active
- 2020-05-27 CN CN202080039617.8A patent/CN113906028A/zh active Pending
- 2020-05-27 PE PE2021001959A patent/PE20220767A1/es unknown
- 2020-05-27 JP JP2021570274A patent/JP2022535734A/ja active Pending
- 2020-05-27 CA CA3138168A patent/CA3138168A1/en active Pending
- 2020-05-27 MX MX2021014575A patent/MX2021014575A/es unknown
-
2021
- 2021-11-05 DO DO2021000230A patent/DOP2021000230A/es unknown
- 2021-11-23 IL IL288322A patent/IL288322A/en unknown
- 2021-11-25 JO JOP/2021/0313A patent/JOP20210313A1/ar unknown
- 2021-11-26 CL CL2021003155A patent/CL2021003155A1/es unknown
- 2021-12-01 CO CONC2021/0016433A patent/CO2021016433A2/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180186789A1 (en) * | 2014-09-08 | 2018-07-05 | Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh | Pyrazolopyridine derivatives and their use in therapy |
| CN107531691A (zh) * | 2014-12-30 | 2018-01-02 | 诺维拉治疗公司 | 治疗乙型肝炎感染的衍生物和方法 |
| WO2018005881A1 (en) * | 2016-06-29 | 2018-01-04 | Novira Therapeutics, Inc. | Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections |
| CN109641896A (zh) * | 2016-06-29 | 2019-04-16 | 诺维拉治疗公司 | 二氮杂酮衍生物及其在治疗乙型肝炎感染中的用途 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024114709A1 (en) * | 2022-12-01 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | A crystal form of a fused heterocycle derivative compound |
| WO2024140851A1 (zh) * | 2022-12-28 | 2024-07-04 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020243135A1 (en) | 2020-12-03 |
| EP3976617B1 (en) | 2025-04-23 |
| BR112021022889A2 (pt) | 2022-01-04 |
| PE20220767A1 (es) | 2022-05-16 |
| CR20210666A (es) | 2022-03-11 |
| PH12021552974A1 (en) | 2022-07-11 |
| DOP2021000230A (es) | 2022-05-31 |
| EP3976617A1 (en) | 2022-04-06 |
| CA3138168A1 (en) | 2020-12-03 |
| CO2021016433A2 (es) | 2021-12-10 |
| BR112021022889A8 (pt) | 2024-03-05 |
| CL2021003155A1 (es) | 2022-07-22 |
| JP2022535734A (ja) | 2022-08-10 |
| MA56043A (fr) | 2022-04-06 |
| MX2021014575A (es) | 2022-05-24 |
| JOP20210313A1 (ar) | 2021-11-25 |
| SG11202113167QA (en) | 2021-12-30 |
| AU2020285718A1 (en) | 2022-02-03 |
| IL288322A (en) | 2022-01-01 |
| KR20220012913A (ko) | 2022-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113906028A (zh) | 稠合杂环衍生物 | |
| KR20180022818A (ko) | 환화 술파모일아릴아미드 유도체 및 b형 간염 치료용 약제로서의 이의 용도 | |
| CN113710667A (zh) | 用于治疗hbv感染或hbv诱发的疾病的稠合环嘧啶酮衍生物 | |
| CN113767101A (zh) | 具有抗乙型肝炎病毒(hbv)活性的新的吲哚-2-甲酰胺类化合物 | |
| US20230076319A1 (en) | Inhibitors of hepatitis b virus | |
| CN117881661A (zh) | 稠合杂环衍生物 | |
| US20220348592A1 (en) | Fused heterocyclic derivatives | |
| CN113906030A (zh) | 稠合杂环衍生物 | |
| HK40066700A (zh) | 稠合杂环衍生物 | |
| JP2022535208A (ja) | 抗ウイルス剤としての縮合ヘテロ環誘導体 | |
| CN113906031A (zh) | 作为衣壳组装调节剂的稠合杂环衍生物 | |
| CN114174300A (zh) | 二氢嘧啶衍生物及其在治疗hbv感染或hbv诱发疾病中的用途 | |
| KR20220015420A (ko) | 캡시드 조립 조절제로서의 디아제피논 유도체 | |
| EA047929B1 (ru) | Сочлененные гетероциклические производные | |
| CN117715909A (zh) | 稠合杂环衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40066700 Country of ref document: HK |
|
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20251031 |
|
| AD01 | Patent right deemed abandoned |